San Diego, CA-based Trovagene Inc. a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today that it has been selected by the Pancreatic Cancer Action Network as the liquid biopsy provider to participate in Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.
“Trovagene was chosen as the Precision Promise liquid biopsy partner for their leadership and innovation in applying KRAS as a real-time indicator of response to therapy,” said Lynn Matrisian, PhD, MBA, Chief Research Officer. “In partnership with Trovagene, we aim to evolve the way diagnostics are used to optimize treatment and improve patient survival.”
The Pancreatic Cancer Action Network is the leading non-profit organization committed to increasing survival for people diagnosed with pancreatic cancer, and is making an initial investment of $35 million to accelerate the clinical trial process to bring promising therapies to patients faster.
As a founding member of the initial Precision Promise Industry Working Group, Trovagene will contribute to sub-study design and future study objectives. The Trovera™ liquid biopsy test will be used as a dynamic tool throughout the course of patient treatment with experimental therapies.
“We’re excited to partner with the Pancreatic Cancer Action Network on this unprecedented initiative. This further validates our approach to how quantitative liquid biopsy testing can be used in real-time to optimize treatment decisions and the timing of treatment changes,” said Mark Erlander, PhD, Chief Scientific Officer of Trovagene.
Source – Trovagene